| P50 | author | André Pèlegrin | Q88939578 |
| | Caroline Bascoul-Mollevi | Q112178184 |
| P2093 | author name string | William Jacot | |
| | Evelyne Lopez-Crapez | |
| | Jean-Pierre Bleuse | |
| | Thierry Chardès | |
| | Jean-François Prost | |
| | Gérard Mathis | |
| | Hervé Bazin | |
| | Florence Boissière-Michot | |
| | Alexandre Ho-Pun-Cheung | |
| | Joëlle Simony-Lafontaine | |
| | Emeline Landas | |
| P2860 | cites work | Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers | Q27001445 |
| | Quantification of HER family receptors in breast cancer | Q27015506 |
| | Untangling the ErbB signalling network | Q27860884 |
| | Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer | Q28481420 |
| | Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy | Q29617584 |
| | Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 |
| | The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation | Q29620694 |
| | Measurement of DNA concentration as a normalization strategy for metabolomic data from adherent cell lines | Q30665370 |
| | EGFR associated expression profiles vary with breast tumor subtype | Q33292502 |
| | mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues | Q33641661 |
| | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | Q33769821 |
| | HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial | Q34194672 |
| | Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens | Q34342079 |
| | Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 |
| | Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer | Q35185688 |
| | Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues. | Q36134039 |
| | Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling | Q36170837 |
| | Molecular classification and molecular forecasting of breast cancer: ready for clinical application? | Q36250255 |
| | Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. | Q36422842 |
| | Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). | Q36649356 |
| | HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. | Q36693285 |
| | Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes | Q37269261 |
| | Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development | Q38768309 |
| | Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET). | Q38947431 |
| | Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. | Q41761158 |
| | Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells | Q42141122 |
| | Prognostic markers in triple-negative breast cancer | Q42505075 |
| | Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry | Q42510173 |
| | Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 |
| | Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis | Q47416389 |
| | HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. | Q50949577 |
| | A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. | Q51824154 |
| | ErbB-3 predicts survival in ovarian cancer. | Q53251670 |
| | High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). | Q53702698 |
| | p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. | Q54982192 |
| | The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality | Q57112021 |
| | Recommendations for Improved Standardization of Immunohistochemistry | Q58376162 |
| | HTRF(R) Technology | Q73851641 |
| | HER2 status and benefit from adjuvant trastuzumab in breast cancer | Q80959592 |
| P433 | issue | 3 | |
| P921 | main subject | triple-negative breast cancer | Q7843332 |
| P304 | page(s) | 397-404 | |
| P577 | publication date | 2019-12-03 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples | |
| P478 | volume | 122 | |